MedPath

effect of Unani formulation in Diabetic patients

Phase 2
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2023/07/055902
Lead Sponsor
Central Council for Research in Unani Medicine(CCRUM)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients of any sex aged of 30-65 years.

Fasting plasma glucose levels between 126 and 175 mg/dL (or)

Post Prandial plasma glucose levels between 200 and 250 mg/dL (or)

HbA1c level between 6.5 and 8% (as per ADA 2010 Criteria)

Presence of any of the following symptoms and signs of diabetes mellitus: Polydipsia, Polyuria, Nocturia, Giddiness, Fatigue, Loss of Weight, Polyphagia & Loss of Libido

Exclusion Criteria

Subjects with FPG level >175 mg/dL and/ or PP plasma glucose level >250 mg/dL and/ or HbA1c >8%

Subjects on Insulin therapy.

Type 2 DM with complications/ Type 1 DM

Significant pulmonary/ cardiovascular/ hepato-renal dysfunction

Known cases of immune-compromised states (HIV/ AIDS, etc.)/ Malignancies

Obese subjects (BMI >30)

Pregnant and lactating women

Drug addicts/ Alcoholics

Patient not willing to attend treatment schedule regularly

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath